Unity Biotechnology Inc

Company Profile

Unity Biotechnology Inc had its IPO on 2018-05-03 under the ticker symbol UBX.

The company operates in the Healthcare sector and Biotechnology industry. Unity Biotechnology Inc has a staff strength of 22 employees.

Stock update

Shares of Unity Biotechnology Inc opened at $2.48 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $2.47 - $2.55, and closed at $2.51.

This is a +1.21% increase from the previous day's closing price.

A total volume of 24,787 shares were traded at the close of the day’s session.

In the last one week, shares of Unity Biotechnology Inc have slipped by -4.2%.

Unity Biotechnology Inc's Key Ratios

Unity Biotechnology Inc has a market cap of $38.26 million, indicating a price to book ratio of 0.5203 and a price to sales ratio of 7.8878.

In the last 12-months Unity Biotechnology Inc’s revenue was $0 with a gross profit of $-35223000 and an EBITDA of $-47076000. The EBITDA ratio measures Unity Biotechnology Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, Unity Biotechnology Inc’s operating margin was 0% while its return on assets stood at -30.63% with a return of equity of -114.05%.

In Q2, Unity Biotechnology Inc’s quarterly earnings growth was a positive 0% while revenue growth was a negative 100%.

Unity Biotechnology Inc’s PE and PEG Ratio

Forward PE

0

Trailing PE

0

PEG

Its diluted EPS in the last 12-months stands at $-3.34 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Unity Biotechnology Inc’s profitability.

Unity Biotechnology Inc stock is trading at a EV to sales ratio of 3.8736 and a EV to EBITDA ratio of 0.2022. Its price to sales ratio in the trailing 12-months stood at 7.8878.

Unity Biotechnology Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets

$101.01 million

Total Liabilities

$22.22 million

Operating Cash Flow

$9.85 million

Capital Expenditure

$0

Dividend Payout Ratio

0%

Unity Biotechnology Inc ended 2023 with $101.01 million in total assets and $0 in total liabilities. Its intangible assets were valued at $101.01 million while shareholder equity stood at $49.41 million.

Unity Biotechnology Inc ended 2023 with $0 in deferred long-term liabilities, $22.22 million in other current liabilities, 1000.00 in common stock, $-483021000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $19.12 million and cash and short-term investments were $69.09 million. The company’s total short-term debt was $13,704,000 while long-term debt stood at $4.08 million.

Unity Biotechnology Inc’s total current assets stands at $72.97 million while long-term investments were $1.90 million and short-term investments were $49.97 million. Its net receivables were $1.74 million compared to accounts payable of $1.45 million and inventory worth $1.76 million.

In 2023, Unity Biotechnology Inc's operating cash flow was $9.85 million while its capital expenditure stood at $0.

Comparatively, Unity Biotechnology Inc paid $0 in dividends in 2023.

Other key metrics

Current Trading Price

$2.51

52-Week High

$5.72

52-Week Low

$1.461

Analyst Target Price

$7.67

Unity Biotechnology Inc stock is currently trading at $2.51 per share. It touched a 52-week high of $5.72 and a 52-week low of $5.72. Analysts tracking the stock have a 12-month average target price of $7.67.

Its 50-day moving average was $2.7 and 200-day moving average was $3.09 The short ratio stood at 7.66 indicating a short percent outstanding of 0%.

Around 143.1% of the company’s stock are held by insiders while 2913.3% are held by institutions.